Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate for GVHD Prophylaxis in Haploidentical HCT
NCT04622956Phase 2Recruiting
- Sponsor
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methotrexate in graft-versus-host disease (GVHD) (2 arms), sponsored by Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Primary endpoints: Methotrexate dose to be used in phase 2 at 30 days and GVHD-free, relapse-free survival at 365 days. Started Oct 2020; status: recruiting.
02
Drugs
methotrexate
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04622956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622956.